JP2023500116A5 - - Google Patents
Info
- Publication number
- JP2023500116A5 JP2023500116A5 JP2022525706A JP2022525706A JP2023500116A5 JP 2023500116 A5 JP2023500116 A5 JP 2023500116A5 JP 2022525706 A JP2022525706 A JP 2022525706A JP 2022525706 A JP2022525706 A JP 2022525706A JP 2023500116 A5 JP2023500116 A5 JP 2023500116A5
- Authority
- JP
- Japan
- Prior art keywords
- trem
- con
- rare
- trna
- codon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930361P | 2019-11-04 | 2019-11-04 | |
| US62/930,361 | 2019-11-04 | ||
| PCT/US2020/058948 WO2021092064A1 (en) | 2019-11-04 | 2020-11-04 | Trem compositions for con-rare codons and related uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023500116A JP2023500116A (ja) | 2023-01-04 |
| JP2023500116A5 true JP2023500116A5 (enExample) | 2023-11-14 |
Family
ID=73654885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525706A Pending JP2023500116A (ja) | 2019-11-04 | 2020-11-04 | ｃｏｎ－希少コドンのためのＴＲＥＭ組成物及び関連する使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220364092A1 (enExample) |
| EP (1) | EP4055163A1 (enExample) |
| JP (1) | JP2023500116A (enExample) |
| KR (1) | KR20220128611A (enExample) |
| CN (1) | CN115003810A (enExample) |
| AU (1) | AU2020379762A1 (enExample) |
| CA (1) | CA3160097A1 (enExample) |
| MX (1) | MX2022005362A (enExample) |
| WO (1) | WO2021092064A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102930465B1 (ko) | 2017-11-02 | 2026-02-25 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | ACE-tRNA를 이용한 유전 재할당을 통한 정지 코돈의 구조 방법 |
| WO2021243301A2 (en) * | 2020-05-29 | 2021-12-02 | Flagship Pioneering Innovations Vi, Llc. | Trem compositions and methods relating thereto |
| KR20230029685A (ko) * | 2020-05-29 | 2023-03-03 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | Trem 조성물 및 이에 관련된 방법 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5801030A (en) | 1995-09-01 | 1998-09-01 | Genvec, Inc. | Methods and vectors for site-specific recombination |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| WO2006105038A2 (en) * | 2005-03-25 | 2006-10-05 | The Uab Research Foundation | Methods of altering gene expression and methods of treatment utilizing same |
| GB0600948D0 (en) * | 2006-01-18 | 2006-02-22 | Univ Dundee | Prevention/Treatment Of Ichthyosis Vulgaris, Atopy And Other Disorders |
| US20120077224A1 (en) * | 2009-06-05 | 2012-03-29 | The Salk Institute For Biological Studies | unnatural amino acid incorporation in eukaryotic cells |
| WO2012006551A2 (en) * | 2010-07-08 | 2012-01-12 | The Brigham And Women's Hospital, Inc. | Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules |
| AU2013327059B2 (en) * | 2012-10-02 | 2018-11-08 | Vaxiion Therapeutics, Llc | Immunomodulatory minicells and methods of use |
| CA2930665A1 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| MA39819A (fr) | 2014-04-01 | 2017-02-08 | Rubius Therapeutics Inc | Méthodes et compositions d'immunomodulation |
| US20180135012A1 (en) | 2015-05-13 | 2018-05-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| SI3402491T1 (sl) | 2016-01-11 | 2022-05-31 | Rubius Therapeutics, Inc. | Sestavki in postopki v zvezi z multimodalnimi terapevtskimi celičnimi sistemi za indikacije raka |
| MX2019000205A (es) | 2016-07-07 | 2019-09-23 | Rubius Therapeutics Inc | Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno. |
| US20180153989A1 (en) | 2016-12-02 | 2018-06-07 | Rubius Therapeutics, Inc. | Compositions and methods related to cell systems for penetrating solid tumors |
| CN110520522A (zh) | 2017-02-17 | 2019-11-29 | 鲁比厄斯治疗法股份有限公司 | 功能化红系细胞 |
| CA3062426A1 (en) | 2017-05-08 | 2018-11-15 | Flagship Pioneering Innovations V, Inc. | Compositions for facilitating membrane fusion and uses thereof |
| WO2020069199A1 (en) * | 2018-09-26 | 2020-04-02 | Case Western Reserve University | Methods and compositions for increasing protein expression and/or treating a haploinsufficiency disorder |
| CA3125567A1 (en) * | 2019-01-18 | 2020-07-23 | Flagship Pioneering, Inc. | Trem compositions and uses thereof |
| WO2020243560A1 (en) * | 2019-05-31 | 2020-12-03 | Flagship Pioneering, Inc. | Uses of trem compositions to modulate trna pools |
-
2020
- 2020-11-04 CA CA3160097A patent/CA3160097A1/en active Pending
- 2020-11-04 US US17/774,410 patent/US20220364092A1/en active Pending
- 2020-11-04 AU AU2020379762A patent/AU2020379762A1/en active Pending
- 2020-11-04 EP EP20817113.2A patent/EP4055163A1/en active Pending
- 2020-11-04 KR KR1020227018837A patent/KR20220128611A/ko active Pending
- 2020-11-04 MX MX2022005362A patent/MX2022005362A/es unknown
- 2020-11-04 WO PCT/US2020/058948 patent/WO2021092064A1/en not_active Ceased
- 2020-11-04 CN CN202080077056.0A patent/CN115003810A/zh active Pending
- 2020-11-04 JP JP2022525706A patent/JP2023500116A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baik et al. | Initial transcriptome and proteome analyses of low culture temperature‐induced expression in CHO cells producing erythropoietin | |
| EP3191526B1 (en) | Wnt signaling agonist molecules | |
| Watanabe | Unique features of animal mitochondrial translation systems–The non-universal genetic code, unusual features of the translational apparatus and their relevance to human mitochondrial diseases– | |
| JP2023500116A5 (enExample) | ||
| Haque et al. | The effect of mutated mitochondrial ribosomal proteins S16 and S22 on the assembly of the small and large ribosomal subunits in human mitochondria | |
| CA2182217A1 (en) | Comparative gene transcript analysis | |
| KR20230020991A (ko) | 최적화된 뉴클레오티드 서열의 생성 | |
| TW202246309A (zh) | 用於靶向蛋白質降解的合成降解系統 | |
| Komar | A code within a code: how codons fine-tune protein folding in the cell | |
| EP4071178A1 (en) | Method for producing peptide having physiological activity, and peptide comprising short linker | |
| Magistrati et al. | Modopathies caused by mutations in genes encoding for mitochondrial RNA modifying enzymes: molecular mechanisms and yeast disease models | |
| US10000548B2 (en) | GAL-1 variants having immuno-modulating properties and methods of using the same | |
| Ryu et al. | Cyanobacteria join the kahalalide conversation: genome and metabolite evidence for structurally related peptides | |
| CN115697373A (zh) | 线粒体衍生肽和其类似物作为包括癌症的年龄相关性疾病的治疗的用途 | |
| WO2018212322A1 (ja) | 遺伝性腎疾患アルポート症候群治療薬に係る評価系 | |
| US20260092258A1 (en) | Method to Rejuvenate Human Cells Through Transcriptional Reprogramming | |
| JP2021048805A (ja) | がんにおける融合遺伝子 | |
| CN116693626A (zh) | 订书肽及其用途和在体外扩增干细胞的方法 | |
| CN119708138B (zh) | 一种仿刺参胶原蛋白肽及其应用 | |
| US20260038688A1 (en) | Methods and systems of plasma cell-free rna as non-invasive biomarkers for parkinson's disease | |
| Hävermark et al. | Dynamic ribosome binding by trigger factor in vivo | |
| Willbold | The purely thermodynamic anti-prionic mode of action for the treatment of neurodegenerative diseases | |
| Hutson et al. | Abstract 1531 Mass spectrometry-based proteomic analysis of glioblastoma-derived extracellular vesicles and healthy brain cells for biomarkers identification | |
| Sîrbulescu et al. | Proteomic characterization of spontaneously regrowing spinal cord following injury in the teleost fish Apteronotus leptorhynchus, a regeneration-competent vertebrate | |
| Guan et al. | Fluorescence and single-particle cryo-EM analysis of ribosome/nascent-globin complexes: Protein-protein interactions and pharmaceutical implications |